JW Pharmaceutical Corporation (001065-KS) Stock Split, History Data
Working capital analysis
In terms of working capital, JW Pharmaceutical Corporation maintains a healthy position.
The total current assets of the company are valued at $378091350382.
This represents a growth rate of -11.133% compared to the previous year.
Breaking down the current assets, the cash and investments are worth $15908868301, exhibiting a growth rate of -53.068% year-on-year.
The receivables, another significant portion of the current assets, are valued at $173629305565.
The year-on-year growth rate for receivables is 7.082%.
The inventory, which forms a critical part of the assets, is valued at $106091353778.
This represents a healthy year-on-year growth of -4.994%
On the liabilities side, the company's current liabilities total $286927113694.
This reflects a growth rate of -24.519% over the previous year, indicating the company's financial obligations are well under control.
2023
2022
2021
2020
2019
2018
Cash and investments
15908.87
33897.93
33366.48
10451.34
41864.25
30948.42
Receavebles
173629.31
162146.19
192840.01
132743.50
189013.37
234798.74
Inventory
106091.35
111668.43
102527.60
101197.79
90442.49
101367.13
Other
5532.66
1963.72
5417.83
10096.27
13737.34
6795.79
Total Current Assets
378091.35
425457.06
366451.50
299328.71
335057.45
373910.08
Acc Payable
73847.21
82907.88
51642.85
47885.39
45087.22
44464.61
Short Term Debt
117404.62
207693.01
123074.57
107315.68
155880.77
128030.97
Other Current Liab
89585.37
82814.89
35045.58
42299.85
37271.21
47181.07
Current Liabilities
286927.11
380131.10
282677.56
234747.63
277983.38
228368.45
Capital Structure
When examining the capital structure of JW Pharmaceutical Corporation, it is clear that the company manages a robust portfolio.
The value of their total assets clocks in at $645038796101.
When juxtaposed with the previous year, this marks a growth rate of 2.718%, showcasing the company's ability to steadily grow its asset base.
Turning to liabilities, the company has total liabilities amounting to $379598339300.
Compared to the prior year, this reflects a growth rate of -5.623%.
The long-term debt forms a sizable part of these liabilities, coming in at $30000000000.
Over the last year, the long-term debt has grown by 1522.228%.
On the asset side, the cash and equivalent reserves are worth $15908868301.
The year-on-year growth of these reserves is -53.068%.
The company's common stock, another important asset, holds a value of $57925902500, growing at a rate of 4.474% from the previous year.
Finally, the company's retained earnings stand at $92612038000, marking a growth rate of 3.907% year-over-year.
These earnings represent the profits that JW Pharmaceutical Corporation has chosen to reinvest in the business rather than distribute as dividends.
Total Assets
$645,038.80
Total liabilities
$379,598,339,300.00
Long term debt
$30,000.00
Cash and eqv
$15,908,868,301.00
Goodwill
$1,404.47
Retained earnings
$92,612,038,000.00
Common stock
$33,578.95
Enterprise Value
$1.97
Historical dividend key summary
JW Pharmaceutical Corporation's dividend per share is $425, showing the earnings shared with shareholders per share. It has grown by 141.859% this year, suggesting that the company is generating increased income for shareholders and expecting future earnings growth.
Years
Q1
Q2
Q3
Q4
Total
2023
0.000
380.735
0.000
425.000
805.735
2022
0.000
333.143
0.000
0.000
333.143
2021
0.000
314.019
0.000
0.000
314.019
2020
0.000
314.019
0.000
0.000
314.019
2019
0.000
314.019
0.000
0.000
314.019
2018
0.000
263.882
0.000
0.000
263.882
2016
0.000
0.000
0.000
227.940
227.940
2015
0.000
0.000
0.000
140.908
140.908
2014
0.000
0.000
0.000
115.027
115.027
2013
0.000
0.000
0.000
109.550
109.550
2012
0.000
0.000
0.000
91.291
91.291
2011
0.000
0.000
0.000
156.500
156.500
2010
0.000
0.000
0.000
215.290
215.290
Net earnings per share (EPS)
JW Pharmaceutical Corporation has an EPS of $1428.63, which signifies the profit allocated per share of common stock. With a growth rate of 97.477% this year, it indicates the company's increasing profitability and potential for share value growth. This trend signals robust financial performance and future potential.
Years
Q1
Q2
Q3
Q4
Total
2023
630.19
531
-767.96
1035.4
1428.63
2022
89.06
9.13
77.05
548.2
723.44
2021
165.8
-138.32
209.32
-63.93
172.87
2020
-112.66
-349.67
121.36
-285.75
-626.72
2019
-192.2
60.68
46.99
-954.79
-1039.32
2018
189.75
350.09
94.78
-303.32
331.30
2017
36.3
-43.73
236.78
-259.89
-30.54
2016
58.43
-667.45
-196.07
355.51
-449.58
2015
19.83
-15.65
44.27
32.2
80.65
2014
61.82
-198.29
23.27
172.7
59.50
2013
28.09
37.89
23.39
4.18
93.55
2012
10.09
-391.29
-81.47
-359.72
-822.39
2011
57.05
24.78
-161.2
-
-79.37
2010
218.67
56.36
32.75
-77.5
230.28
2009
210.88
146.78
-36.71
128.03
448.98
2008
179.63
180.32
4.55
-99.18
265.32
2007
191.32
209.9
114.57
-155.54
360.25
Brief information
JW Pharmaceutical Corporation (001065.KS) stock split history
Understanding the historical stock splits of JW Pharmaceutical Corporation (001065.KS) provides insights into its past financial decisions and investor sentiment. A stock split occurs when a company increases its share count by dividing its existing shares. The most recent split took place on December 27, 2023 with a ratio of 1:1. Throughout its history, the company has undergone 15 stock splits. Below, we delve deeper into this history, highlighting past financial strategies.
